Media centre

Vernalis signs research agreement with AstraZeneca

17 October 2003

Vernalis today announced that it has signed an initial research agreement with AstraZeneca. Under the agreement between the two companies, AstraZeneca will use Vernalis' structure-based drug discovery (SBDD) technology to investigate a number of proprietary AstraZeneca compounds against certain anti-infective drug targets. Financial terms were not disclosed.

The Vernalis SBDD technology platform exploits the detailed molecular structure of drug targets to drive the discovery and design of novel therapeutic molecules. Novel compounds are discovered through a combination of proprietary molecular docking calculations and fragment-based methods. High throughput crystallographic methods reveal the atomic detail of the binding mode of the compounds, guiding rational design of the desired drug-like properties. The effective integration of these structural, computational and medicinal chemistry methods allows rapid progression of lead candidate molecules, improving the quality and speed of the drug discovery process.

Commenting on the agreement, Mr Simon Sturge, Chief Executive Officer of Vernalis stated: \"We are delighted to be collaborating with AstraZeneca in structure-based drug discovery. This is an example of how our leading-edge technology can be applied.\"

Dr Mark Wuonola, Director of Infection Strategy, Infection Discovery at AstraZeneca said: \"Vernalis offered us a unique way to progress our understanding of compounds that are of great interest to AstraZeneca as potential new anti-infective drugs. We look forward to working with their structure-based drug discovery experts.\"

The SBDD technology was developed by RiboTargets and acquired by British Biotech in April 2003 as part of their merger. British Biotech then merged with Vernalis Group plc in July 2003, and the combined group is now known as Vernalis.

----ends----

Latest News

Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership

Vernalis plc and Servier are pleased to announce that they reinforce their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch